JP2024522766A - 縮合四環系化合物、その調製方法及びその医薬的応用 - Google Patents

縮合四環系化合物、その調製方法及びその医薬的応用 Download PDF

Info

Publication number
JP2024522766A
JP2024522766A JP2023577689A JP2023577689A JP2024522766A JP 2024522766 A JP2024522766 A JP 2024522766A JP 2023577689 A JP2023577689 A JP 2023577689A JP 2023577689 A JP2023577689 A JP 2023577689A JP 2024522766 A JP2024522766 A JP 2024522766A
Authority
JP
Japan
Prior art keywords
group
cancer
compound
salt
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522766A5 (cg-RX-API-DMAC7.html
Inventor
心 李
峰 沈
懐徳 董
陽 陳
峰 賀
維康 陶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2024522766A publication Critical patent/JP2024522766A/ja
Publication of JP2024522766A5 publication Critical patent/JP2024522766A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023577689A 2021-06-21 2022-06-21 縮合四環系化合物、その調製方法及びその医薬的応用 Pending JP2024522766A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110687643 2021-06-21
CN202110687643.8 2021-06-21
CN202110880105 2021-08-02
CN202110880105.0 2021-08-02
CN202111073775.8 2021-09-14
CN202111073775 2021-09-14
CN202111225928 2021-10-21
CN202111225928.6 2021-10-21
PCT/CN2022/100016 WO2022268051A1 (zh) 2021-06-21 2022-06-21 稠合四环类化合物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
JP2024522766A true JP2024522766A (ja) 2024-06-21
JP2024522766A5 JP2024522766A5 (cg-RX-API-DMAC7.html) 2025-07-01

Family

ID=84544976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577689A Pending JP2024522766A (ja) 2021-06-21 2022-06-21 縮合四環系化合物、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US20240327434A1 (cg-RX-API-DMAC7.html)
EP (1) EP4361157A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024522766A (cg-RX-API-DMAC7.html)
KR (1) KR20240024903A (cg-RX-API-DMAC7.html)
CN (1) CN117255793B (cg-RX-API-DMAC7.html)
AU (1) AU2022297474A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024646A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220929A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023015533A (cg-RX-API-DMAC7.html)
TW (1) TW202317587A (cg-RX-API-DMAC7.html)
WO (1) WO2022268051A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510022A (ja) * 2021-03-17 2024-03-05 ▲勁▼方医▲薬▼科技(上海)有限公司 ピリミジン縮合環系化合物、その製造方法、及び使用
JP2024525993A (ja) * 2021-07-23 2024-07-12 スゾウ、ザンロン、ファーマ、リミテッド Kras g12d阻害剤およびその使用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116867792A (zh) * 2021-02-09 2023-10-10 基因泰克公司 四环氧氮杂䓬化合物及其用途
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
CN118019746A (zh) * 2021-09-27 2024-05-10 北京加科思新药研发有限公司 多环稠环衍生物及其用途
JP2025504041A (ja) * 2022-01-30 2025-02-06 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド キノリン系化合物及びその使用
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
KR20250034087A (ko) * 2022-07-09 2025-03-10 블로썸힐 테라퓨틱스, 인크. 질병 치료를 위한 융합 고리 kras 억제제
TW202409051A (zh) * 2022-07-27 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環類化合物、其製備方法及其在醫藥上的應用
KR20250037564A (ko) * 2022-07-29 2025-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Kras g12d 억제제를 포함하는 약학적 조성물
CN119585278A (zh) * 2022-08-05 2025-03-07 杭州中美华东制药有限公司 具有KRas G12D抑制作用的化合物
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
TW202426459A (zh) * 2022-09-23 2024-07-01 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
TW202440594A (zh) * 2022-12-07 2024-10-16 大陸商北京加科思新藥研發有限公司 稠環化合物及其用途
TW202430184A (zh) * 2022-12-20 2024-08-01 大陸商江蘇恒瑞醫藥股份有限公司 Kras g12d抑制劑的結晶形式及製備方法
WO2024149214A1 (en) * 2023-01-10 2024-07-18 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
WO2024159471A1 (en) * 2023-02-02 2024-08-08 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
WO2024234360A1 (en) * 2023-05-18 2024-11-21 Nikang Therapeutics , Inc. Tetracyclic derivatives as kras inhibitors
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2024208305A1 (zh) * 2023-04-07 2024-10-10 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2024213979A1 (en) * 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024218686A1 (en) * 2023-04-20 2024-10-24 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
JP2026522894A (ja) * 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
JP2026523268A (ja) 2023-07-13 2026-07-13 上海森▲輝▼医▲葯▼有限公司 Kras g12d中間体の調製方法
CN121843945A (zh) * 2023-07-18 2026-04-10 泰励生物科技(上海)有限公司 具有抗kras突变肿瘤活性的化合物
WO2025045141A1 (en) * 2023-08-31 2025-03-06 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
CN122228262A (zh) * 2023-11-02 2026-06-16 金橘生物科技公司 降解剂及其用途
WO2025108443A2 (en) * 2023-11-23 2025-05-30 Beigene Switzerland Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025146194A1 (en) * 2024-01-05 2025-07-10 Jacobio Pharmaceuticals Co., Ltd. Fused tetracyclic compounds and use thereof
AU2025209726A1 (en) * 2024-01-17 2026-07-09 Suzhou Zanrong Pharma Limited Kras inhibitors and uses thereof
CN119684315B (zh) * 2024-01-26 2026-05-12 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
WO2025157261A1 (zh) * 2024-01-26 2025-07-31 江苏恒瑞医药股份有限公司 G12d抑制剂化合物晶型及其制备方法
CN119490512B (zh) * 2024-01-26 2026-06-16 苏州盛迪亚生物医药有限公司 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN119661555B (zh) * 2024-01-26 2026-04-14 苏州盛迪亚生物医药有限公司 一种稠环类化合物的可药用盐、其结晶形式及用途
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag G12c変異型rasタンパク質を阻害するヘテロアリール化合物
WO2021000885A1 (zh) * 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022173678A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
WO2022194245A1 (zh) * 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN110869358A (zh) * 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
TW202012415A (zh) * 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN113874374B (zh) 2019-05-24 2024-12-27 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CN117083281A (zh) * 2021-03-24 2023-11-17 南京明德新药研发有限公司 嘧啶并杂环类化合物及其应用
WO2022206723A1 (zh) * 2021-03-30 2022-10-06 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
CN115557974A (zh) * 2021-07-02 2023-01-03 上海迪诺医药科技有限公司 Kras g12d抑制剂及其应用
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
WO2023025116A1 (zh) * 2021-08-25 2023-03-02 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
TW202315626A (zh) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 嘧啶并環類化合物及其製法和用途
WO2023103906A1 (zh) * 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
JP2025504041A (ja) * 2022-01-30 2025-02-06 シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド キノリン系化合物及びその使用
EP4511127A1 (en) * 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN119365467A (zh) * 2022-05-19 2025-01-24 基因泰克公司 氮杂-四环氧氮杂䓬化合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag G12c変異型rasタンパク質を阻害するヘテロアリール化合物
WO2021000885A1 (zh) * 2019-07-01 2021-01-07 江苏恒瑞医药股份有限公司 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022173678A1 (en) * 2021-02-09 2022-08-18 Genentech, Inc. Tetracyclic oxazepine compounds and uses thereof
WO2022194245A1 (zh) * 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510022A (ja) * 2021-03-17 2024-03-05 ▲勁▼方医▲薬▼科技(上海)有限公司 ピリミジン縮合環系化合物、その製造方法、及び使用
JP2024525993A (ja) * 2021-07-23 2024-07-12 スゾウ、ザンロン、ファーマ、リミテッド Kras g12d阻害剤およびその使用

Also Published As

Publication number Publication date
EP4361157A4 (en) 2024-10-16
MX2023015533A (es) 2024-01-23
KR20240024903A (ko) 2024-02-26
EP4361157A1 (en) 2024-05-01
TW202317587A (zh) 2023-05-01
WO2022268051A1 (zh) 2022-12-29
CN117255793B (zh) 2026-06-12
CA3220929A1 (en) 2022-12-29
BR112023024646A2 (pt) 2024-03-05
US20240327434A1 (en) 2024-10-03
AU2022297474A1 (en) 2024-01-18
CN117255793A (zh) 2023-12-19

Similar Documents

Publication Publication Date Title
KR20240024903A (ko) 융합된 사환식 화합물, 이에 대한 제조 방법 및 의학에서 이의 적용
JP2025524846A (ja) 縮合環系化合物、その調製方法及びその医薬的使用
EP4592295A1 (en) Pyrimidine-fused ring compound, and preparation method therefor and use thereof
CN117486901A (zh) 稠合哌啶类化合物、其制备方法及其在医药上的应用
AU2024372323A1 (en) Fused heteroaryl compound, preparation method therefor, and use thereof in medicine
CN115385937A (zh) 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用
JP2026515630A (ja) ピリド[4,3-d]ピリミジン化合物
CN115368383A (zh) 稠合含氮杂环类化合物、其制备方法及其在医药上的应用
WO2022228543A1 (zh) 桥环类化合物、其制备方法及其在医药上的应用
WO2021203768A1 (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN113980032A (zh) 稠合四环类衍生物、其制备方法及其在医药上的应用
WO2024208305A1 (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN120230123A (zh) 稠环类化合物、其制备方法及其在医药上的应用
JP2024519188A (ja) 含窒素複素環系化合物、その調製方法及びその医薬的応用
WO2021249475A1 (zh) 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
CN120365289A (zh) 稠环类化合物、其制备方法及其在医药上的应用
CN114907377A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN114907349A (zh) 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
TW202246260A (zh) 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN114685429A (zh) 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用
JP2026059772A (ja) ピリド[4,3-d]ピリミジン化合物
CN114456173A (zh) 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用
CN120829440A (zh) 多环类化合物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260609